Seattle Genetics is advancing a proprietary pipeline of ADC programs, including brentuximab vedotin (SGN-35), which is in an ongoing pivotal trial for relapsed or refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma. Seattle Genetics is also developing a number of preclinical ADCs, including SGN-75, which the company is advancing towards a planned 2009 IND submission for CD70-positive hematologic malignancies and solid tumors. The company is also developing ASG-5ME in collaboration with Agensys, a subsidiary of Astellas Pharma. An IND submission of ASG-5ME for solid tumors is planned in the first half of 2010.

ADCs utilize the targeting ability of monoclonal antibodies to deliver potent, cell-killing payloads to specific cells. Seattle Genetics ™ technology employs synthetic, highly potent drugs attached to antibodies through proprietary linker systems. The linkers are designed to be stable in the bloodstream but to release the drug payload under specific conditions once inside target cells, thereby sparing non-target cells many of the toxic effects of traditional chemotherapy.

seagen